Skip to main content

Table 1 Characteristics of studies included in the systematic review

From: Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis

Trial Country Patients, n Female (%) Age, years BMI, kg/m2 Follow up (weeks) Baseline for LDL-C(mg/dl) Characteristics of patients Dose of bempedoic acid
Ballantyne 2013 US 177 44.6 57.5 28.2 12 166.2 No stain used 40, 80, or 120 mg daily
Gutierrez 2014 US 60 38.3 55.7 29.9 12 126.8 No stain used 180 mg daily
Thompson 2015 US 56 50.0 63.5 29.7 12 179.05 Statin intolerant 120 mg, 180 mg, or 240 mg
Ballantyne 2016 US 133 59.4 57.3 30.3 12 135.6 Stable statin background therapy 180 mg daily
Thompson 2016 US 149 71.1 59.7 29.7 12 163.9 With or without statin intolerant 120 mg or 180 mg
Ballantyne 2018 US 269 61.3 63.8 29.8 12 127.6 Statin intolerance 180 mg daily
Laufs 2019 Germany 345 50.4 65.2 30.3 24 157.6 Statin intolerance 180 mg daily
Ray 2019 UK 2230 27.0 66.1 NR 52 103.2 Maximally tolerated statin therapy 180 mg daily
Ballantyne 2019 US 129 50.4 65.1 30.6 12 148.08 Maximally tolerated statin therapy 180 mg daily
Goldberg 2019 US 779 36.3 64.3 30.2 52 120.4 Maximally tolerated statin therapy 180 mg daily
Lalwani 2019 US 64 48.4 58.0 31.0 4 76.4 High-intensity statin background therapy 180 mg daily
  1. NR not reported, BMI body-mass index, LDL- low-density lipoprotein cholesterol